Lyka Labs Limited
NSE: LYKALABS BSE: LYKALABS
Prev Close
105.35
Open Price
109
Volume
17,891
Today Low / High
104 / 109
52 WK Low / High
96.8 / 176.59
Range
99 - 110
Prev Close
105.55
Open Price
105.55
Volume
2,784
Today Low / High
104 / 107.35
52 WK Low / High
90.2 / 175.95
Range
100 - 110
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 104.57 (target range: 99 - 110), reflecting a change of -0.78 (-0.74039%). On the BSE, it is listed at 105 (target range: 100 - 110), showing a change of -0.55 (-0.52108%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Lyka Labs Limited Graph
Lyka Labs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Lyka Labs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 104.57, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 105.00 | 106.05 | 95.45 - 116.66 |
| 107.10 | 85.68 - 128.52 | ||
| 108.15 | 75.71 - 140.60 | ||
| Bearish Scenario | 105.00 | 103.95 | 93.56 - 114.35 |
| 102.90 | 82.32 - 123.48 | ||
| 101.85 | 71.30 - 132.41 |
Overview of Lyka Labs Limited
ISIN
INE933A01014
Industry
Biotechnology
Vol.Avg
54,194
Market Cap
3,732,103,300
Last Dividend
0
Official Website
IPO Date
1996-01-01
DCF Diff
-37.76
DCF
142
Financial Ratios Every Investor Needs
Stock Dividend of LYKALABS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 1996-08-12 | August 12, 96 | 2.5 | 2.5 | 1996-09-10 | 1996-10-01 | 1996-08-12 |
| 1995-09-11 | September 11, 95 | 2.5 | 2.5 | 1995-09-11 | 1995-10-01 | 1995-08-22 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 140.73 Cr | 55.59 Cr | 85.14 Cr | 0.6050 | 0.00 Cr | 0.00 Cr | 50.50 Cr | 8.01 Cr | 2.22 | 20.17 Cr | 0.0569 |
| 2024-03-31 | 106.18 Cr | 45.19 Cr | 60.99 Cr | 0.5744 | 0.00 Cr | 2.58 Cr | 2.55 Cr | -2.49 Cr | -0.75 | 16.76 Cr | -0.0234 |
| 2023-03-31 | 88.34 Cr | 37.55 Cr | 50.78 Cr | 0.5749 | 0.00 Cr | 2.88 Cr | 2.44 Cr | -13.21 Cr | -4.57 | 12.85 Cr | -0.1496 |
| 2022-03-31 | 183.59 Cr | 53.30 Cr | 130.28 Cr | 0.7097 | 0.00 Cr | 3.20 Cr | 83.09 Cr | 39.00 Cr | 13.59 | 101.18 Cr | 0.2124 |
| 2021-03-31 | 67.11 Cr | 38.18 Cr | 28.92 Cr | 0.4310 | 0.00 Cr | 2.25 Cr | 11.36 Cr | -11.55 Cr | -4.07 | 20.12 Cr | -0.1722 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.34 Cr | 176.21 Cr | 72.62 Cr | 103.5502 Cr | 39.18 Cr | 37.84 Cr | 12.47 Cr | 77.10 Cr | 0.00 Cr | 0.00 Cr | 0.02 Cr | 46.6313 Cr |
| 2024-03-31 | 5.95 Cr | 156.72 Cr | 88.46 Cr | 68.1543 Cr | 58.65 Cr | 52.70 Cr | 9.57 Cr | 71.12 Cr | 0.56 Cr | 0.00 Cr | 0.07 Cr | 37.6402 Cr |
| 2023-03-31 | 11.71 Cr | 151.52 Cr | 105.85 Cr | 45.4406 Cr | 74.63 Cr | 62.92 Cr | 6.95 Cr | 63.76 Cr | 0.00 Cr | 0.00 Cr | 0.04 Cr | 32.5980 Cr |
| 2022-03-31 | 1.35 Cr | 185.61 Cr | 172.12 Cr | 13.3384 Cr | 129.66 Cr | 128.31 Cr | 8.20 Cr | 85.97 Cr | 0.00 Cr | 0.00 Cr | 0.01 Cr | 99.3527 Cr |
| 2021-03-31 | 0.24 Cr | 190.01 Cr | 215.10 Cr | -25.7967 Cr | 162.63 Cr | 162.40 Cr | 4.31 Cr | 84.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 49.8809 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.8994 Cr | -11.7960 Cr | 5.2920 Cr | -13.7554 Cr | -4.6047 Cr | 1.3441 Cr | -15.6548 Cr | 8.0120 Cr | -24.2695 Cr | 0.0000 Cr | -2.8937 Cr |
| 2024-03-31 | 1.7733 Cr | -9.4881 Cr | 1.9528 Cr | -7.4581 Cr | -5.7620 Cr | 5.9488 Cr | -9.2314 Cr | -2.4894 Cr | -15.9830 Cr | 0.0000 Cr | -2.6175 Cr |
| 2023-03-31 | 8.9526 Cr | 7.3504 Cr | -21.6427 Cr | 0.7672 Cr | -5.3397 Cr | 11.7108 Cr | -8.1854 Cr | -13.1711 Cr | -56.7815 Cr | 0.0000 Cr | 1.2439 Cr |
| 2022-03-31 | 79.2461 Cr | -6.1720 Cr | -63.1773 Cr | 71.7333 Cr | 9.8969 Cr | 17.0505 Cr | -7.5129 Cr | 59.2470 Cr | -40.1915 Cr | 0.0000 Cr | -3.8919 Cr |
| 2021-03-31 | 8.8115 Cr | -0.1613 Cr | -11.7982 Cr | 7.5438 Cr | -3.1480 Cr | 7.1536 Cr | -1.2678 Cr | -14.1441 Cr | -4.9130 Cr | 0.0000 Cr | 2.4266 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 34.25 Cr | 13.08 Cr | 21.16 Cr | 0.6180 | 11.55 Cr | 1.77 Cr | 0.49 | 5.18 Cr | 0.0517 |
| 2024-12-31 | 33.80 Cr | 13.06 Cr | 20.74 Cr | 0.6136 | 3.36 Cr | 2.71 Cr | 0.75 | 6.02 Cr | 0.0801 |
| 2024-09-30 | 41.16 Cr | 17.95 Cr | 23.21 Cr | 0.5640 | 3.19 Cr | 2.10 Cr | 0.58 | 4.98 Cr | 0.0509 |
| 2024-06-30 | 30.11 Cr | 21.45 Cr | 8.67 Cr | 0.2878 | 1.95 Cr | 1.44 Cr | 0.40 | 4.27 Cr | 0.0478 |
| 2024-03-31 | 27.77 Cr | 22.10 Cr | 5.67 Cr | 0.2042 | -1.24 Cr | -1.94 Cr | -0.64 | 2.14 Cr | -0.0698 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.34 Cr | 0.02 Cr | 1.36 Cr | 43.08 Cr | 12.47 Cr | 67.43 Cr | 77.10 Cr | 176.21 Cr | 72.62 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.13 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -98.69 Cr |
| 2024-09-30 | 1.11 Cr | 5.52 Cr | 6.64 Cr | 0.00 Cr | 9.69 Cr | 58.65 Cr | 74.81 Cr | 168.25 Cr | 69.56 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 6.29 Cr | 0.00 Cr | 0.00 Cr | 6.29 Cr | 0.00 Cr | 0.00 Cr | -68.27 Cr |
| 2024-03-31 | 5.95 Cr | 0.02 Cr | 5.97 Cr | 26.99 Cr | 9.57 Cr | 50.65 Cr | 71.12 Cr | 156.72 Cr | 88.46 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 2.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 2.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1.44 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -1.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹343.35 | ₹459,045,216,000.00 | ₹5,837,972.00 |
| Syngene International Limited | SYNGENE | ₹655.25 | ₹262,994,346,794.00 | ₹428,010.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹190.07 | ₹252,650,205,374.00 | ₹3,554,229.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,598.00 | ₹167,176,687,600.00 | ₹56,810.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹805.10 | ₹139,657,009,642.00 | ₹553,262.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹700.80 | ₹111,624,124,800.00 | ₹206,694.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹657.75 | ₹52,937,561,700.00 | ₹100,129.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹236.15 | ₹37,024,305,450.00 | ₹55,320.00 |
| Zota Health Care Limited | ZOTA | ₹1,202.70 | ₹35,435,751,450.00 | ₹54,284.00 |
| Panacea Biotec Limited | PANACEABIO | ₹409.45 | ₹25,079,099,115.00 | ₹117,574.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1987
Gender: male
Year Born: 1960
FAQs about Lyka Labs Limited
The CEO is Kunal Narendra Gandhi.
The current price is ₹104.57.
The range is ₹96.8-176.59.
The market capitalization is ₹373.21 crores.
The P/E ratio is 47.16.
The company operates in the Healthcare sector.
Overview of Lyka Labs Limited (ISIN: INE933A01014) is a leading Biotechnology in India. With a market capitalization of ₹373.21 crores and an average daily volume of 54,194 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.